Posted by Michael Wonder on 30 Jan 2022
BeiGene announces acceptance of supplemental new drug application in China for Brukinsa (zanubrutinib) in chronic lymphocytic leukaemia with breakthrough therapy designation
28 January 2022 - Brukinsa was granted its first breakthrough therapy designation in China with this application.
BeiGene today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) as a treatment for adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma and granted Brukinsa breakthrough therapy designation.
